Axsome Therapeutics (AXSM) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.99
- Estimate
- -$0.84
- Surprise
- -17.2%
- Revenue (period 2026-06-30)
- $218.4M
- Score today
- 5.8/10
Revenue source: xbrl.
How the report landed
Axsome Therapeutics (AXSM) reported a wider loss than forecast — adjusted EPS of -$0.99 against the -$0.84 estimate (a 17.2% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates AXSM Sell at 5.8/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's -17.2% surprise compares with a +2.9% four-quarter average. Next scheduled report: 2027-02-22.
What argues against it
- Quality below floor (3.6 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $139.61
- Price target
- $247.97
- Stop
- $129.84
- Upside to target
- +77.6%
- Reward-to-risk
- 6.5:1
Risk check: RSI 23 — a level conventionally read as oversold; trading volume is running 1.5× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-11-04 — shown for context, not personalized investment advice.
AXSM at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $7.34B
- P/E (fwd)
- 34.7
- 52-week range
- $123.00–$260.19
- Off 52-week high
- 46.3%
- RSI (14)
- 23
- Volume vs avg
- 1.53×
- Score today
- 5.8/10